{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:04:07Z","timestamp":1794330247421,"version":"4.9.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","award":["22961"],"award-info":[{"award-number":["22961"]}],"id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008721","name":"University College London Hospitals NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.xcrm.2025.102247","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T14:37:13Z","timestamp":1753281433000},"page":"102247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["IgA2+ B cells and IgA2 anti-dsDNA antibodies are selectively targeted by belimumab after rituximab therapy in systemic lupus erythematosus"],"prefix":"10.1016","volume":"6","author":[{"given":"Daniel","family":"McCluskey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad R.A.","family":"Shipa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashfia","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-743X","authenticated-orcid":false,"given":"Michael R.","family":"Ehrenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102247_bib1","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149095","article-title":"Meant to B: B cells as a therapeutic target in systemic lupus erythematosus","volume":"131","author":"Atisha-Fregoso","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102247_bib2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.xcrm.2025.102247_bib3","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.xcrm.2025.102247_bib4","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/art.38074","article-title":"Elevated Serum BAFF Levels Are Associated With Rising Anti\u2013Double-Stranded DNA Antibody Levels and Disease Flare Following B Cell Depletion Therapy in Systemic Lupus Erythematosus","volume":"65","author":"Carter","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.xcrm.2025.102247_bib5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL system in SLE pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.xcrm.2025.102247_bib6","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.7326\/M21-2078","article-title":"Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus","volume":"174","author":"Shipa","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.xcrm.2025.102247_bib7","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2665-9913(22)00332-0","article-title":"Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial","volume":"5","author":"Shipa","year":"2023","journal-title":"Lancet. Rheumatol."},{"key":"10.1016\/j.xcrm.2025.102247_bib8","article-title":"Quest for the holy grail: biomarkers in SLE","volume":"5","year":"2023","journal-title":"The Lancet Rheumatology"},{"key":"10.1016\/j.xcrm.2025.102247_bib9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1128\/CVI.00475-09","article-title":"Expression of homing receptors on IgA1 and IgA2 plasmablasts in blood reflects differential distribution of IgA1 and IgA2 in various body fluids","volume":"17","author":"Pakkanen","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.xcrm.2025.102247_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13992-8","article-title":"IgA subclasses have different effector functions associated with distinct glycosylation profiles","volume":"11","author":"Steffen","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102247_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.xcrm.2025.102247_bib12","article-title":"Human IgA binds a diverse array of commensal bacteria","volume":"217","author":"Sterlin","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2025.102247_bib13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41590-020-0602-z","article-title":"Distinct microbial and immune niches of the human colon","volume":"21","author":"James","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2025.102247_bib14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ebiom.2018.12.035","article-title":"B cell alterations during BAFF inhibition with belimumab in SLE","volume":"40","author":"Ramsk\u00f6ld","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.xcrm.2025.102247_bib15","article-title":"IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE","volume":"9","author":"Wang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102247_bib16","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1172\/JCI91250","article-title":"B cells expressing the transcription factor T-bet drive lupus-like autoimmunity","volume":"127","author":"Rubtsova","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102247_bib17","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s41590-024-01798-w","article-title":"Thioredoxin is a metabolic rheostat controlling regulatory B cells","volume":"25","author":"Bradford","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2025.102247_bib18","article-title":"Differences in management approaches for lupus nephritis within the UK","volume":"8","author":"Ibrahim","year":"2024","journal-title":"Rheumatol. Adv. Pract."},{"key":"10.1016\/j.xcrm.2025.102247_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.555","article-title":"Rituximab utilization for approved and off-label nononcology indications and patients\u2019 experiences with the Patient Alert Card","volume":"8","author":"Sarsour","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.xcrm.2025.102247_bib20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/eji.201646861","article-title":"BAFF augments IgA2 and IL-10 production by TLR7\/8 stimulated total peripheral blood B cells","volume":"48","author":"Den Hartog","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102247_bib21","article-title":"The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies","volume":"3","author":"Cheung","year":"2023","journal-title":"Front. Nephrol."},{"key":"10.1016\/j.xcrm.2025.102247_bib22","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41423-024-01178-2","article-title":"The protective roles of integrin \u03b14\u03b27 and Amphiregulin-expressing innate lymphoid cells in lupus nephritis","volume":"21","author":"Ryu","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.xcrm.2025.102247_bib23","first-page":"80","article-title":"Antigenic stimulation during pregnancy modifies specific iga1 and iga2 subclasses in human colostrum according to the chemical composition of the antigen","volume":"72","author":"S\u00e1nchez-Salguero","year":"2020","journal-title":"Rev. Invest. Clin."},{"key":"10.1016\/j.xcrm.2025.102247_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren's syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2025.102247_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.602539","article-title":"Single-Cell Transcriptomic Analyses Define Distinct Peripheral B Cell Subsets and Discrete Development Pathways","volume":"12","author":"Stewart","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102247_bib26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.immuni.2022.01.002","article-title":"Development of Tbet- and CD11c-expressing B cells in a viral infection requires T follicular helper cells outside of germinal centers","volume":"55","author":"Song","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2025.102247_bib27","doi-asserted-by":"crossref","first-page":"18550","DOI":"10.1073\/pnas.1901340116","article-title":"Excessive CD11c(+)Tbet(+) B cells promote aberrant T(FH) differentiation and affinity-based germinal center selection in lupus","volume":"116","author":"Zhang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102247_bib28","doi-asserted-by":"crossref","first-page":"7305","DOI":"10.1073\/pnas.1917834117","article-title":"Evidence for a pathogenic role of extrafollicular, IL-10-producing CCR6(+)B helper T cells in systemic lupus erythematosus","volume":"117","author":"Facciotti","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102247_bib29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41591-018-0254-9","article-title":"A CD4+ T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate","volume":"25","author":"Caielli","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102247_bib30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/eji.201646861","article-title":"BAFF augments IgA2 and IL-10 production by TLR7\/8 stimulated total peripheral blood B cells","volume":"48","author":"den Hartog","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.xcrm.2025.102247_bib31","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.3390\/ijms21103463","article-title":"Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus","volume":"21","author":"Parodis","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2025.102247_bib32","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/ard-2024-225686","article-title":"Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study","volume":"83","author":"Aranow","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.xcrm.2025.102247_bib34","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with Harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2025.102247_bib35","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1186\/s12864-018-4772-0","article-title":"Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics","volume":"19","author":"Street","year":"2018","journal-title":"BMC Genom."},{"key":"10.1016\/j.xcrm.2025.102247_bib36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","article-title":"Dictionary learning for integrative, multimodal and scalable single-cell analysis","volume":"42","author":"Hao","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2025.102247_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting Linear Mixed-Effects Models Using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J. Stat. Software"},{"key":"10.1016\/j.xcrm.2025.102247_bib38","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.169584","article-title":"Ancestry-based differences in the immune phenotype are associated with lupus activity","volume":"8","author":"Slight-Webb","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2025.102247_bib33","doi-asserted-by":"crossref","first-page":"748","DOI":"10.12688\/f1000research.11622.1","article-title":"CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets","volume":"6","author":"Nowicka","year":"2017","journal-title":"F1000Res."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125003209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125003209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T21:40:05Z","timestamp":1762638005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125003209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2666379125003209"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102247","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IgA2+ B cells and IgA2 anti-dsDNA antibodies are selectively targeted by belimumab after rituximab therapy in systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102247"}}